Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.395
-0.015 (-1.06%)
Feb 12, 2026, 3:04 PM EST - Market open
Ocugen Revenue
Ocugen had revenue of $1.75M in the quarter ending September 30, 2025, with 54.23% growth. This brings the company's revenue in the last twelve months to $5.37M, up 14.26% year-over-year. In the year 2024, Ocugen had annual revenue of $4.06M, down -32.82%.
Revenue (ttm)
$5.37M
Revenue Growth
+14.26%
P/S Ratio
77.41
Revenue / Employee
$56,526
Employees
95
Market Cap
457.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zevra Therapeutics | 84.39M |
| ADC Therapeutics | 75.21M |
| Verastem | 13.38M |
| Prothena Corporation | 11.79M |
| Lineage Cell Therapeutics | 10.82M |
| 4D Molecular Therapeutics | 120.00K |
| vTv Therapeutics | 17.00K |
OCGN News
- 3 days ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire
- 20 days ago - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - GlobeNewsWire
- 21 days ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 22 days ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha
- 4 weeks ago - Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
- 4 weeks ago - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 4 weeks ago - Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - GlobeNewsWire